Open AccessBook
Decision Modelling for Health Economic Evaluation
Andrew Briggs,Karl Claxton,Mark Sculpher +2 more
- 17 Aug 2006
2.9K
TL;DR: This book deals with decision modelling techniques that can be used to estimate the value for money of various interventions including medical devices, surgical procedures, diagnostic technologies, and pharmaceuticals.
read more
Abstract: 1. Introduction 2. Key aspects of decision modelling for economic evaluation 3. Further developments in decision analytic models for economic evaluation 4. Making decision models probabilistic 5. Analysing and presenting simulation output from probabilistic models 6. Decision-making, uncertainty and the value of information 7. Efficient research design 8. Future challenges for cost-effectiveness modelling of health care interventions
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Costs and outcomes of increasing access to bariatric surgery for obesity: cohort study and cost-effectiveness analysis using electronic health records
Martin Gulliford,Martin Gulliford,Judith Charlton,Helen P Booth,Alison Fildes,Omar Khan,Marcus Reddy,Mark Ashworth,Peter Littlejohns,A Toby Prevost,A Toby Prevost,Caroline Rudisill +11 more
TL;DR: Diverse obese individuals may benefit from bariatric surgery at acceptable cost, but increased health care costs are exceeded by health benefits to obese individuals.
29
Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis
TL;DR: In the Italian setting and according to the guidelines of the Italian Association of Health Economics (IAHE), belimumab was shown to be cost-effective, in terms of both ICER and ICUR, (€25–40,000/QALY).
Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
Charung Muangchana,Arthorn Riewpaiboon,Suchada Jiamsiri,Piyanit Thamapornpilas,Porpit Warinsatian +4 more
TL;DR: The Thai National Vaccine Committee, through the Immunization Practice Subcommittee, has conducted an economic analysis, aiming to estimate the costs of rotavirus diarrhea and of a rotav virus vaccination program, and the cost-effectiveness of such a program including budget impact analysis.
29
The cost-effectiveness of routine follow-up after primary total hip arthroplasty
Katharina Merollini,Ross Crawford,Bill Donnelly,Sarah L. Whitehouse,Nicholas Graves +4 more
- 01 Jan 2009
TL;DR: If there is no routine follow-up of patients for 7 years after primary THA, there would be cost savings and gains of between 1.8 and 8.8 quality-adjusted life years.
29
High-sensitive Troponin T assay for the diagnosis of acute myocardial infarction: an economic evaluation
Anil H. Vaidya,Anil H. Vaidya,Johan L. Severens,Brenda W. C. Bongaerts,Kitty B.J.M. Cleutjens,Patty J. Nelemans,Leonard Hofstra,Marja P. van Dieijen-Visser,Erik A.L. Biessen +8 more
TL;DR: Assessment of the cost effectiveness of a high-sensitive Troponin T assay alone or combined with the heart-type fatty acid-binding protein (H-FABP) assay in comparison with the conventional cardiac Trop onin (cTnT) assay suggests that hsTNT assay is a very cost effective diagnostic tool relative to conventional TnT assay.